Dysthyroid optic neuropathy: Atypical initial presentation and persistent visual loss

Orbit

Volumn 28, Issue 6, 2009, Pages 354-362

  Mensah, Aurore ^a   Vignal Clermont, Catherine ^a   Chadi, Mehanna ^a   Xavier, Morel ^a   Olivier, Galatoire ^a   Pierre Vincent, Jacomet ^a   Serge, Morax ^a  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Altitudinal field defect; Dysthyro d optic neuropathy; Graves' orbitopathy; Prognostic; Steroid treatment

Indexed keywords

STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DECOMPRESSION SURGERY; DEMOGRAPHY; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; MALE; VISION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

AGE OF ONSET; DECOMPRESSION, SURGICAL; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OPTIC NERVE DISEASES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VISION DISORDERS; VISUAL ACUITY;

EID: 71249139483     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830903104728     Document Type: Article

References (35)

1. Boulos PR, Hardy I. Thyroid-associated orbitopathy: A clinicopathologic and therapeutic review. Current Opinion in Ophthalmology. 2004; 15: 389-400
2. Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J ophthalmol. 1995; 119 (6): 792-795
3. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in olmsted County, Minnesota. Trans am Ophthalmol Soc. 1994; 92: 477-588
4. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. The incidence of Graves' ophthalmopathy in Olmsted county, Minnesota. Am J Ophthalmol. 1995 ;120(4): 511-7
5. Mc Keag D, Lane CM, LazarusJH, Badelschi L, Mourits MP, Wiersinga WM et al. Clinical features of dysthyroid optic neuropathy: A European group on Graves' orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2007; 91: 455-458
6. Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Arch Ophthalmol. 1978; 96: 1199-1209
7. Neigel JM, RootmanJ, Belkin RI, Nugent RA, Drance SM, Beattie C, Spinelli. Dysthyroid optic neuropathy : the crowded orbital apex syndrome. Ophthalmology. 1988; 95: 1515-1521
8. Kennerdell JS, Rosenbaum AE, El-Hoshy MH. Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography. Arch Ophthamol. 1981; 99 (5): 807-809
9. Riemann CD, Foster JA, Kosmorsky GS. Direct orbital manometry in patients with thyroid-associated orbitopathy. Ophthalmology. 1999; 106: 1296-1302
10. Danesh-Meyer HV, Savino PJ, Deramo V, Sergott RC, Smith AF. Intraocular pressure changes after treatment for Graves' orbitopathy. Ophthalmolgy. 2001; 108 (1): 145-150
11. Otto AJ, Koorneef L, Mourits MP, Deen-van Leeuwen L. Retrobulbar pressures measured during surgical decompression of the orbit. Br J Ophthalmol. 1996 Dec; 80 (12): 1042-1045
12. Winstanley J. Visual field defects in dysthyroid eye disease and their management in Cant JS (ed) : the optic nerve; proceedings of the second William Mc Kenzie Memorial Symposium. St Louis, CV Mosby Co, 1972: 230-236
13. Boghen DR, Glaser JS. Ischemic optic neuropathy- the clinical profile and natural history. Brain. 1975; 98: 689-708
14. Glatt HJ. Optic nerve dysfunction in thyroïd eye diseases : A clinician 's perspective. Radiology. 1996; 200: 26-27
15. Soares-Welch CV, Fatourechi V, Bartley GB, Beatty CW, Gorman CA, Bahn RS, et al. Optic neuropathy of Graves disease : results of a transantral orbital decompression and long-term follow up in 215 patients. Am J ophthalmol. 2003; 136: 433-441
16. Walkelkamp MJ, Badelschit L, Saeedt P, Mouritd MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as first-line treatment of optic neuropathy in Graves' ophthalmopathy ? a randomized controlled trial. Clin Endocrinol. 2005; 63: 323-328
17. Prummel MF, baker A, Wiersinga WM, Badelschi L, Mourits MP, Kendall-Taylor P, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy : the first European group on Graves orbitopathy experience. Eur J Endocrinol. 2003; 148 (5): 491-495
18. Prummel MF, Mourits MP, Blank L, Berghout A, Koomneef L, Wiersinga WM. Randomized double blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993; 342 (8877): 949-954
19. Mourits MP, Koorneef L, Wiersinga WM, Prummel MF, Berghout A, Van Der Gang R. Clinical criterias for the assessment of Graves' disease orbitopathy activity : A novel approach. Br J ophthalmol. 1989; 73 (8): 639-644
20. Feldon SE, Muramatsu S, Weiner JM. Clinical classification for Graves Ophthalmopathy : identification of risk factors for optic neuropathy. Arch ophthalmol. 1984; 102: 1469-1472
21. Thierry J Hufnagel, Williamn F Hickey, Walter H Cobbs, Frederick A, et al. Immunohistochemical and ultrastructural studies of the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology. 1999; 106: 1296-1302
22. Rotella CM, Alvarez F, Kohn LD, Toccafoni R. Graves' autoantibodies to extrathyroidal TSH receptors : their role in ophthalmopathy and pretibial myxoedema. Acta Endocrinol Metab. 1973; 37: 17-24
23. Heufelder A. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disorders. 2000; 1: 87-90
24. Kazim M, Goldberg RA, Smith TJ. Insight to the pathogenesis of thyrois associated ophthalmopathy. Arch Ophthalmol. 2002; 120: 380-386
25. Vestergaard P. Smoking and thyroid disorders : A metaanalysis. Eur J Endocrinol. 2002; 146: 153-161
26. Kimball L, Kulinskaya E, Brown B, et al. Does smoking increase relapse rate in Graves' disease ? J Endocrinol Invest. 2002; 25: 152-157
27. Ellenberger C, Keltner JL, Burde RM. Acute optic neuropathy in older patients. Arch neurol. 1973; 28: 182-185
28. Hayreh SS, Joss KM, Podhajsky PA, B.S.N, Long CR. Systemic diseases associated with non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994; 118: 766-780
29. Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology. 2001; 108: 1586-1594
30. Rush S, Winterkorn JM, Zak R. Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease. Int J Radiat Oncol Biol Phys. 2000; 47: 191-194
31. Morax S, Bok C, Chahbi M, Hurbli T. Orbital decompression in exophthalmos due to thyroid disease. Report of 69 cases. Ann Chir Plast Esthet. 1997 ;42(3): 207-215
32. Morax S, Hurbli T. Choice of treatement for Graves' disease. J Craniomaxillofac Surg. 1987;15: 174 :81
33. Hutchinson BM, Kyle PM. Long-term visual outcome following orbital decompression for dysthyroid eye disease. Eye. 1995 ;9(Pt5): 578-581
34. Salvi M, Spaggiari E, Neri F, Macaluso C, Gardini E, Ferrozzi F, et al. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement. J Clin Endocrinol Metab. 1997 ; 82(4): 1027
35. Tsaloumas MD, Good PA, Burdon MA, Misson GP. Flash and pattern visual evoked potentials in the diagnosis and monitoring of dysthyroid optic neuropathy. Eye. 1994; 8 (Pt 6): 638-645